Cowen analyst Boris Peaker reiterated an Outperform rating on Fate Therapeutics (NASDAQ: FATE) and sees high probability of positive data at ASH.

Peaker commented, "Fate provided a pipeline update on its 3Q15 call as well as an overview of its strategic plans with the new CEO. At ASH Fate will present a second interim look at ProHema's PUMA study and highlight new early-stage pipeline platforms. We see a high probability of positive data ASH."

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $4.52 yesterday.